Regado Biosciences Priced, Nasdaq: RGDO
Developing break-through anticoagulant system for cardiovascular surgeries.
Industry: Health Care
First Day Return: +17.5%
Industry: Health Care
RGDO
Developing break-through anticoagulant system for cardiovascular surgeries.
| IPO Data | |
|---|---|
| IPO File Date | 04/29/2013 |
| Offer Price | $4.00 |
| Price Range $5.00 - $5.00 | |
| Offer Shares (mm) | 10.8 |
| Deal Size ($mm) | $43 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 08/21/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $43 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Basking Ridge, NJ, United States |
| Founded | 2001 |
| Employees at IPO | 30 |
| Website www.regadobio.com | |
IPO News for Regado Biosciences
Regado Biosciences (RGDO) Performance
